InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

Current share price for RCE : $0.335 0.005 (1.52%)+

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$102 Conversion of Performance Shares 16 Jun 2022 5:48PM $0.605 $0.335 fallen by 44.63%
$102 Cleansing Statement 1 Jun 2022 12:29PM $0.770 $0.335 fallen by 56.49%
$102 Application for quotation of securities - RCE 1 Jun 2022 12:26PM $0.770 $0.335 fallen by 56.49%
$102 Phase I Clinical Trial R327 Advances to 4000mg 20 May 2022 9:54AM $0.815 $0.335 fallen by 58.90%
$102 MDC: Biotech Investors Luncheon Presentations 16 May 2022 3:34PM $0.785 $0.335 fallen by 57.32%
$102 Corporate Presentation - Biotech Investor Lunch 16 May 2022 11:12AM $0.775 $0.335 fallen by 56.77%
$102 GTG: Biotech Investors Presentation 16 May 2022 9:07AM $0.785 $0.335 fallen by 57.32%
$102 Quarterly Activities/Appendix 4C Cash Flow Report 2 May 2022 9:43AM $0.900 $0.335 fallen by 62.78%
$102 Cleansing Statement 12 Apr 2022 2:03PM $0.920 $0.335 fallen by 63.59%
$102 Application for quotation of securities - RCE 12 Apr 2022 1:59PM $0.920 $0.335 fallen by 63.59%
$102 Phase I Clinical Trial R327 Advances to High Dose Cohort 12 Apr 2022 10:08AM $0.940 $0.335 fallen by 64.36%
$102 Anti-Viral Patent Granted in Hong Kong 11 Apr 2022 10:46AM $0.940 $0.335 fallen by 64.36%
$102 Cleansing Statement 1 Apr 2022 5:44PM $0.930 $0.335 fallen by 63.98%
$102 Application for quotation of securities - RCE 1 Apr 2022 5:35PM $0.930 $0.335 fallen by 63.98%
$102 Positive safety data from 4th Cohort -Phase I Clinical Trial 30 Mar 2022 10:05AM $0.950 $0.335 fallen by 64.74%
$102 $3.08m R&D Rebate Received 28 Mar 2022 11:46AM $0.940 $0.335 fallen by 64.36%
$102 Safety Committee Clears PhI R327 Dose Increase 7 Mar 2022 9:58AM $0.915 $0.335 fallen by 63.39%
$102 S&P DJI Announces March 2022 Quarterly Rebalance 4 Mar 2022 5:02PM $0.915 $0.335 fallen by 63.39%
$102 Appendix 4D and Interim Financial Report 28 Feb 2022 6:31PM $1.000 $0.335 fallen by 66.50%
$102 Positive Safety Continues in 3rd Cohort PhI Clinical Trial 21 Feb 2022 9:39AM $1.085 $0.335 fallen by 69.12%
$102 Cleansing Statement 11 Feb 2022 5:30PM $1.150 $0.335 fallen by 70.87%
$102 Notification regarding unquoted securities - RCE 11 Feb 2022 5:21PM $1.150 $0.335 fallen by 70.87%
$102 Application for quotation of securities - RCE 11 Feb 2022 5:04PM $1.150 $0.335 fallen by 70.87%
$102 Positive Safety Data from Third Cohort of PI Clinical Trial 8 Feb 2022 10:06AM $1.240 $0.335 fallen by 72.98%
$102 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2022 11:06AM $1.175 $0.335 fallen by 71.49%

301 - 325 of 729 results

Page 13 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.